North American Vaccine Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine

NVX 1.410

-6.6%

Nov 3 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Don W Stone who wrote (3)	10/11/1996 7:07:00 PM
From: Nidarius Foxworth	of 82

D. Stone- Sorry for the delay in responding. I have been out of the country and unable to access the WWW. I'm not sure about the whole NVX situation. I usually don't get involved in such complex stories... I am not an expert in the vaccine market and do not have the time to do the necessary research. All in all the NVX story seems really messy... and there are plenty of other investment opp.'s out there which are a touch cleaner. Of course, the messiness of the whole thing is what makes it interesting to observe. Once there was a company called Alfacell. They were working on a product dubbed PANNON during the 1980's (they might still be in business). One great man by the name of Martin Blyseth was very fond of educating the public about PANNON and all its promise. You remind me of him. In an effort to keep historical facts straight so that our Blysethien truth-seekers who wade through the mire of messiness don't waste time getting tangled up in a fallacious chain of hypothetical "what ifs", I did a little modest fact checking. I called up Sturza's Medical Letter and asked the question: has Sturza ever covered a Short position? The answer: Sturza has covered short positions. In April 1995, he covered GNSA at $3.19 after having shorted it at over $30 per share. After he covered the short position, he actually recommended buying the stock. Subsequently, it went up to around $5 at which price he decided to close the long position. Again, I would urge you to call the publisher of Sturza's Medical Letter with any questions you have about their reports and past performance/recommendations. You'd probably get a more accurate and timely reply than waiting for me to answer. With all these complicated issues you're thinking about, it does seem rather silly to leave such simple questions unanswered and waste time defending Sturza with erroneous statements about clients' best interests. I close with some words which I think you might appreciate: "Lest we forget: This is a story of which fairy tales are made... and dreamers rewarded." -Martin Blyseth

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next